As businesses continue to navigate the health and economic
challenges posed by the COVID-19 pandemic, annual shareholder
meeting dates are approaching for most public companies.
Accordingly, where annual director equity grants are made on the
date of the annual shareholder meeting, boards of directors should
carefully consider, with guidance from their legal advisors and
compensation consultants, whether any adjustments to director
compensation programs are necessary in response to recent market
turbulence.
We have listed key considerations we believe boards of directors
should examine in connection with this review, particularly in
light of the current environment of investor and activist scrutiny
and the risk of Delaware breach of fiduciary duty claims related to
director compensation.